Background-The prevalence of synchron-
The occurrence of more than one lung cancer in a patient is an unusual event. Most commonly in such patients a second (metachronous) tumour develops after treatment of the initial, presenting carcinoma.'2 Patients having more than one primary lung carcinoma at presentation (synchronous pulmonary neoplasms) are distinctly less common. -5 We present a review of the clinical and pathological findings in a series of 19 patients found to have two or more separate primary tumours at the time of lobectomy or pneumonectomy. The study was undertaken with the particular objective of determining the effect such a presentation might have on a patient's prognosis.
Methods
All resection specimens for lung cancer received in the pathology department of the University of Edinburgh over seven years were retrieved. Reports on the gross anatomy were examined to identify cases in which at least two distinct tumour masses were described by the reporting pathologist. These cases were reviewed histologically. All specimens had been fixed by formalin distension and then sagittally sectioned, thus allowing for full inspection of small airways and the pulmonary parenchyma. Synchronous tumours were distinguished from intrapulmonary metastases by the following criteria. (a) Total physical separation of the lesions within the lung was essential to avoid confusion with carcinomas of mixed differentiation. (b) Distinct tumour masses of different histological subtypes were automatically considered to be synchronous neoplasms. (c) Where all the lesions were squamous carcinomas a synchronous classification was accepted if a separate origin from an area of carcinoma in situ could be identified for each.
A different approach was also used where tumours were of the same histological subtype. Archival paraffin embedded tissue from each lesion was processed for DNA flow cytometry according the standard protocol.67 The nuclear suspensions were stained with propidium iodide and analysed on an EPICS CS (Coulter) flow cytometer. At least 10 000 nuclei were analysed from each specimen. The resulting DNA histograms were classified as diploid or DNA aneuploid. The latter were defined by the presence of a second G0IGj peak on the histogram differing in channel number from the diploid peak by at least 10%. Only histograms with a coefficient of variation of less than 7 on the diploid peak were accepted for analysis. Patients with differences in DNA index between distinct tumour masses were accepted as having synchronous tumours.
Details of smoking history and clinical outcome were obtained from the patients' hospital charts and, when necessary, from general practitioners or tumour registry databanks, or both. The preoperative chest radiographs were also reviewed in each case.
Results
In all, 1029 lobectomies or pneumonectomies for lung cancer were performed in the years under study. More than one distinct tumour mass was identified in 24 cases (2.3%).
Histologically, one patient had three squamous carcinomas, nine patients had two squamous carcinomas, two had two distinct adenocarcinomas, six had squamous and adenocarcinomas, three had squamous and small cell carcinomas, two had squamous and atypical carcinoid tumours (well differentiated neuroendocrine carcinomas), and one patient had an adenosquamous carcinoma in combination with a classical carcinoid tumour.
Five patients were excluded from the study by not fulfilling our criteria for tumour synchrony. Three of these were in the group of 10 cases with more than one squamous carcinoma mass as they showed no have come to light in various ways, both radiographically (presentation with obvious dual lesions'3) and pathologically (either from surgical material or in the course of postmortem studies' '5). The aim of the present study was to ascertain the prevalence of synchronous tumours solely in the context of surgical material and to determine the effect of such a finding on survival.
The criteria for diagnosis of synchronous tumours in the lung vary from study to study. All authors agree that a clear plane of separation between tumour masses is essential. Similarly, the coexistence of discrete tumour masses of different histological subtypes is widely accepted as evidence of separate origins. Many authors exclude cases in which there is more than one tumour of a given histological type, arguing that the second tumour cannot reliably be distinguished from an intrapulmonary metastasis. Although this is indeed often the case we agree with Martini and Melamed3 that distinct squamous carcinomas can often be distinguished by identifying separate origins from areas of carcinoma in situ. The advent of DNA flow cytometry has introduced the possibility of further distinguishing such tumours by detecting tumour differences between tumours in DNA stemlines. This technique has been shown to be of use in renal as well as in pulmonary carcinomas.'1 '6 The incidence of synchronous carcinomas in the lung, as defined by the above criteria, is just under 2% of all cases coming to surgery in Edinburgh. As the pneumonectomy or lobectomy specimens examined in each case can never represent more than about half of the patient's lung tissue this figure is likely to underestimate the true incidence of synchronous tumours in the general population presenting with lung cancer. In this regard it is worth noting that the age and sex distribution of the patients included in this study, their smoking histories and the chest radiographs at presentation were not remarkable. That none of the patients had a preoperative radiological diagnosis of possible synchronous tumours may reflect an inclination among physicians not to refer patients with more than one pulmonary lesion for surgical resection. It is therefore perhaps not surprising that in the 18 cases where accurate tumour measurements were available the smaller tumour was staged as T1 in 11 cases (62%). Most of these lesions measured no more than 1 cm (maximum diameter).
All of the patients were followed to their deaths. The overall prognosis for the group was dismal, with a 41% (7/17) three year and 6% (1/17) five year survival-even though only two patients had mediastinal node affected (N2 disease) at the time of resection.
The adverse prognosis is in keeping with a previously published account by Deschamps et al from the Mayo Clinic,4 who observed that patients presenting with synchronous carcinomas had a worse prognosis than those patients having second resections for metachronous tumours developing after an initial non-small cell lung cancer had been treated surgically.
Perhaps the most important result to come out of our study is the finding that the generally bleak outlook for patients found to have synchronous primary pulmonary neoplasms does not appear to apply to those having carcinomas all of squamous type. This difference is statistically significant despite the small numbers. The better prognosis in patients with synchronous squamous tumours is in keeping with the generally acknowledged more favourable outlook for lung tumours of squamous type. In fact, most of the patients with synchronous squamous carcinomas died without evidence of tumour recurrence. We conclude that the pathologist's detection of more than one primary carcinoma in surgical resection specimens from patients with lung cancer is an indicator of poor prognosis except in patients presenting with multiple squamous carcinomas, when a somewhat less guarded prognosis would seem appropriate. 
